Problem Solving Breakout Discussions
In Silico Modelling in IO, How Useful and Predictive?
Moderator: Armin Sepp, PhD, Scientific Leader and GSK Fellow, IVIVT DMPK Modelling, GlaxoSmithKline
- Target engagement in combination and bispecific therapies, when can one or the other be preferred?
- Tumour penetration of biotherapeutics
- Drug interactions with innate and adaptive immune system cells
How Can We Leverage Cutting Edge In Vivo Pre-Clinical Models for Cancer Immunotherapy Profiling?
Moderator: Sara Colombetti, PhD, Global Head of Oncology Discovery Pharmacology, Pharma Research and Early Development (pRED), Roche Innovation Center Zurich
- Current limitations of pre-clinical mouse models for cancer immuno-therapy
- How can CPI resistant patient population can be modeled pre-clinically
- New frontiers of tumor immuno-profiling
Why Digital Biomarkers?
Moderator: Daniel R. Karlin, MD, MA, CEO, HealthMode, Inc.
- What measurements are improved with digital tools?
- Better, Faster, More Robust? Sorting hype from reality in digital tools
- Regulatory aspects and challenges
Immunotherapies Beyond Melanoma and Lung Cancers
Moderator: Sheeba Irshad, MD, PhD, Senior Clinical Lecturer, Cancer and Pharmaceutical Sciences, Kings College London
- Strategies for converting cold tumours into hot tumours
- Coordinated clinical trial designs of immunotherapies
- Immunotherapy combinations
The Tumour Microenvironment (TME) And Its Ability to Influence Monoclonal Antibody Effector Functions
Moderator: Sophia N. Karagiannis, BA, MS, PhD, Professor, Translational Cancer Immunology and Immunotherapy, School of Basic & Medical Biosciences, King’s College London
- Antibody engagement of effector cells in the TME
- The role of cancer cells in influencing the modulatory state of effector cells and Fc receptors
- Engineering of antibodies to overcome immunosuppressive forces in the TME
What Are the Mechanisms of Immune Exclusion and What We Need to Know About Them?
Moderator: Franco Marincola, PhD, Chief Scientific Officer, Refuge Biotechnologies
- Discuss the kind of barriers that prevent T cells from infiltrating tumors
- Physical barriers
- Functional barriers
- Dynamic barriers
How do we Effectively Develop Immunotherapy Combinations for Cancer?
Moderator: Johan Lantto, PhD, Project and Portfolio Director, Immuno-Oncology, Symphogen
- Immunotherapy has shown impressive results in various cancer indications, however, only a subset of patients respond to single agent therapy.
- Combination immunotherapy presents an opportunity for improving responses and outcomes for cancer patients.
- The development of immunotherapy combinations faces a number of preclinical, clinical and regulatory challenges, which will be discussed in the breakout session.
Immunogenicity of Bispecific Antibodies
Moderator: Anne Mansson-Kvarnhammar, PhD, Senior Scientist, Alligator Bioscience AB
- What challenges could one expect for novel bispecific scaffolds in terms of immunogenicity?
- What can be done to test this early to avoid immunogenicity in the clinic?
- What is the usefulness and “predictability” of in silico and in vitro assays to predict clinical immunogenicity of IO antibodies?
Going Beyond Bispecifics – Trispecific Antibodies and Other “Multispecific” Approaches
Moderator: Matthew J. Bernett, PhD, Associate Director, Protein & Antibody Engineering, Xencor, Inc.
- What are the opportunities for using multispecifics
- What challenges would one expect for multispecifics
- Which benefits are expected when using multispecifics
- Which approaches are enabled by multispecifics and which ones remain impossible?
Novel Strategies for Overcoming Antigen Heterogeneity for Enhancing CAR T Cell Efficacy
Moderator: Phil Darcy, PhD, Professor, NHMRC Principal Research Fellow, Laboratory Head Cancer Immunotherapy, Peter MacCallum Cancer Centre
- Preclinical work using armored CAR T cells. Discussion of different cytokines that have been used in this format.
- Discussion of strategy using dual expressing CAR T cells to overcome antigen heterogeneity.
- Translational feasibility of these new approaches
Are Innate Immune Cells More Tolerant of the Tumour Microenvironment than T Cells?
Moderator: Mark Lowdell, PhD, Director, Centre for Cell, Gene & Tissue Therapeutics, RFH; Professor, Cell & Tissue Therapy, University College London
- Effects of hypoxia on NK, CAR-NK, Gamma delta T cell and monocyte activation
- Direct and indirect effects of Treg on NK function
- Role of MDSC in innate immune suppression in the TME